Parathormone (PTH) has been suggested to affect the cardiovascular system. Teriparatide (TPT), the hormonally active 1-34 fragment of PTH, provides an anabolic treatment for osteoporosis. The aim of the present study was to evaluate the cardiometabolic effects of 18-month treatment with 20 μg/ die teriparatide subcutaneosly. Fourteen women with postmenopausal severe osteoporosis treated with once-daily sc 20 μg TPT (67.6±2.5 years; BMI 27.7±1.0 kg/m2) and 24 age- and BMI-matched severe osteoporotic women treated with iv yearly 5 mg zoledronate (ZLN) were evaluated at baseline and at 12-18 months of treatment for anthropometric measures, calcium, glucose and lipid metabolic parameters, and assessment of cardiac geometry by conventional echocardiography. TPT was effective in increasing mean lumbar spine bone mineral density with no clinically relevant changes in calcium metabolism parameters. TPT patients experienced an increase of BMI (27.7±1.0 at baseline vs 29.0±1.0 kg/m2 at last evaluation, P=0.005) and mean whole body fat percentage (37.0±2.1 vs 40.3±1.9%, P=0.05), associated with increased serum leptin levels (17.3±2.1 vs 22.9±3.0 ng/ml; P=0.049). Glucose and lipid parameters were not affected by TPT as well as by ZLN treatment. Furthermore, TPT was associated with a decrease in systolic blood pressure; a decrease in the fractional shortening (41.2±2.3 vs 36.9±1.2; P=0.05) and an increase in the relative wall thickness (0.39±0.01 vs 0.48±0.01 mm; P=0.002), suggestive for concentric cardiac remodeling, was detected by echocardiographic monitoring. These changes could not be detected in bone active drug-free age- and metabolic-matched controls. In conclusion, long-term TPT therapy might affect cardiometabolic and cardiac geometry parameters in severe osteoporotic women, though changes are not clinically relevant.

Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women / E. Passeri, E. Dozio, M. Mendola, E. Costa, F. Bandera, M. Corsi Romanelli, S. Corbetta. - In: JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS. - ISSN 0393-974X. - 29:4(2015), pp. 931-940.

Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women

E. Passeri;E. Dozio;F. Bandera;M. Corsi Romanelli;S. Corbetta
2015

Abstract

Parathormone (PTH) has been suggested to affect the cardiovascular system. Teriparatide (TPT), the hormonally active 1-34 fragment of PTH, provides an anabolic treatment for osteoporosis. The aim of the present study was to evaluate the cardiometabolic effects of 18-month treatment with 20 μg/ die teriparatide subcutaneosly. Fourteen women with postmenopausal severe osteoporosis treated with once-daily sc 20 μg TPT (67.6±2.5 years; BMI 27.7±1.0 kg/m2) and 24 age- and BMI-matched severe osteoporotic women treated with iv yearly 5 mg zoledronate (ZLN) were evaluated at baseline and at 12-18 months of treatment for anthropometric measures, calcium, glucose and lipid metabolic parameters, and assessment of cardiac geometry by conventional echocardiography. TPT was effective in increasing mean lumbar spine bone mineral density with no clinically relevant changes in calcium metabolism parameters. TPT patients experienced an increase of BMI (27.7±1.0 at baseline vs 29.0±1.0 kg/m2 at last evaluation, P=0.005) and mean whole body fat percentage (37.0±2.1 vs 40.3±1.9%, P=0.05), associated with increased serum leptin levels (17.3±2.1 vs 22.9±3.0 ng/ml; P=0.049). Glucose and lipid parameters were not affected by TPT as well as by ZLN treatment. Furthermore, TPT was associated with a decrease in systolic blood pressure; a decrease in the fractional shortening (41.2±2.3 vs 36.9±1.2; P=0.05) and an increase in the relative wall thickness (0.39±0.01 vs 0.48±0.01 mm; P=0.002), suggestive for concentric cardiac remodeling, was detected by echocardiographic monitoring. These changes could not be detected in bone active drug-free age- and metabolic-matched controls. In conclusion, long-term TPT therapy might affect cardiometabolic and cardiac geometry parameters in severe osteoporotic women, though changes are not clinically relevant.
postmenopausal osteoporosis; teriparatide; glucose; lipids; cardiac geometry; body weight
Settore MED/05 - Patologia Clinica
Settore MED/13 - Endocrinologia
JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS
Article (author)
File in questo prodotto:
File Dimensione Formato  
52 JBRHA 2015 proof.pdf

non disponibili

Tipologia: Altro
Dimensione 794.01 kB
Formato Adobe PDF
794.01 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/362018
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact